Biosimilars: Evidential Standards for Health Technology Assessment

被引：11
|
作者：
Hughes, D. A. [1 ]
机构：
[1] Bangor Univ, Ctr Econ & Policy Hlth, Inst Med & Social Care Res, Bangor, Gwynedd, Wales
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷 / 03期
基金：
英国医学研究理事会;
关键词：
ANTIBODIES;
D O I：
10.1038/clpt.2009.112
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：257 / 261
页数：5
相关论文
共 50 条
  • [1] Health technology assessment of biosimilars worldwide: a scoping review
    Ascef, Bruna de Oliveira
    Lopes, Ana Carolina de Freitas
    de Soarez, Patricia Coelho
    HEALTH RESEARCH POLICY AND SYSTEMS, 2020, 18 (01)
  • [2] Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann, Dominika
    Jablecka, Anna
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (06) : 781 - 792
  • [3] Health technology assessment of biosimilars worldwide: a scoping review
    Bruna de Oliveira Ascef
    Ana Carolina de Freitas Lopes
    Patrícia Coelho de Soárez
    Health Research Policy and Systems, 18
  • [4] A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS
    Balijepalli, C.
    Desai, K.
    Yan, K.
    Zoratti, M.
    Marshall, L.
    White, N.
    Franklin, M.
    Druyts, E.
    VALUE IN HEALTH, 2019, 22 : S810 - S810
  • [5] HEALTH TECHNOLOGY ASSESSMENT LANDSCAPE OF BIOSIMILARS - APPROACHES TO EVALUATIONS AND RESULTS
    Andreykiv, M.
    Dahal, D.
    VALUE IN HEALTH, 2013, 16 (03) : A4 - A4
  • [6] Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making?
    Ascef, Bruna de Oliveira
    Leonel da Silva, Renan Goncalves
    de Oliveira Junior, Haliton Alves
    De Soarez, Patricia Coelho
    CADERNOS DE SAUDE PUBLICA, 2019, 35 (09):
  • [7] Biosimilars Tackle Interchangeability Standards
    Mirasol, Feliza
    BIOPHARM INTERNATIONAL, 2020, 33 (04) : 28 - 32
  • [8] THE REGISTRY EVALUATION AND QUALITY STANDARDS TOOL (REQUEST) FOR HEALTH TECHNOLOGY ASSESSMENT FROM AN OUTCOMES ASSESSMENT PERSPECTIVE
    Gimenez, E.
    Espallargues, M.
    Rodrigues, J.
    Varela, L.
    Patrick, H.
    Jae, L.
    Maja, V
    Guzina, I
    VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [9] Biosimilars' Technology Needs
    Langer, Eric
    BIOPHARM INTERNATIONAL, 2011, 24 (11) : 16 - +
  • [10] Global Regulatory Standards for the Approval of Biosimilars
    Mounho, Barbara
    Phillips, Audrey
    Holcombe, Kay
    Grampp, Gustavo
    Lubiniecki, Tony
    Mollerup, Inger
    Jones, Carolyn
    FOOD AND DRUG LAW JOURNAL, 2010, 65 (04) : 819 - 837
12345